Taken together, our results suggest that fibulin-3 targeting decreases immunosuppressive signals in GBM cells, whereas anti–fibulin-3–mediated opsonization allows macrophage attack of the tumor cells, both effects that can be achieved with mAb428.2. This evidence concerns the gene EFEMP1 and glioblastoma.